NERISSA VAZQUEZ ARROYO: Open Payments
NPI 1174025449 · HONOLULU, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,580 in 71 payments from 13 companies in 2025. Trend: 2023 $987 · 2024 $1,587 · 2025 $2,580
Food & beverage: $2,580
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 33 | $691 |
| Madrigal Pharmaceuticals | 15 | $638 |
| Janssen Biotech, Inc. | 6 | $254 |
| Ipsen Biopharmaceuticals, Inc | 4 | $224 |
| GENZYME CORPORATION | 2 | $171 |
| Mallinckrodt Hospital Products Inc. | 1 | $146 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| AstraZeneca Pharmaceuticals LP | 1 | $122 |
| Mirum Pharmaceuticals, Inc. | 2 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $60 |
Products named: REZDIFFRA, TREMFYA, IQIRVO, DUPIXENT, TERLIVAZ, ZENPEP, Vemlidy, Livmarli.
Industry payments across HI — which companies pay providers there.
